TriSalus Life Sciences (NASDAQ:TLSIW) Stock Price Down 12.3% – Time to Sell?

TriSalus Life Sciences, Inc. (NASDAQ:TLSIW)’s share price dropped 12.3% on Thursday . The stock traded as low as $1.00 and last traded at $0.8590. Approximately 437 shares changed hands during trading, a decline of 91% from the average daily volume of 4,770 shares. The stock had previously closed at $0.98.

TriSalus Life Sciences Trading Down 12.3%

The company’s 50-day moving average price is $1.32 and its two-hundred day moving average price is $1.34.

Institutional Trading of TriSalus Life Sciences

Institutional investors and hedge funds have recently made changes to their positions in the stock. Aristeia Capital L.L.C. purchased a new stake in shares of TriSalus Life Sciences during the 4th quarter valued at $43,000. Fort Baker Capital Management LP purchased a new stake in shares of TriSalus Life Sciences during the 4th quarter valued at $44,000. Citadel Advisors LLC raised its position in shares of TriSalus Life Sciences by 439.0% during the 3rd quarter. Citadel Advisors LLC now owns 126,876 shares of the company’s stock valued at $199,000 after buying an additional 103,336 shares in the last quarter. Finally, Cerity Partners LLC purchased a new stake in shares of TriSalus Life Sciences during the 4th quarter valued at $1,374,000.

About TriSalus Life Sciences

TriSalus Life Sciences, Inc is a clinical-stage medical device company focused on developing minimally invasive technologies to enhance the precision and efficacy of cancer radiation therapy. The company’s lead product, the TriMark™ Tissue Marker System, is designed to provide high-visibility soft-tissue fiducial markers that assist oncologists in accurately targeting tumors during radiotherapy. By deploying bio-absorbable markers directly into tumor beds, TriSalus aims to improve treatment planning, patient comfort and long-term follow-up imaging.

Founded in 2015 and headquartered in Plymouth, Minnesota, TriSalus Life Sciences pursues a platform approach to oncology treatment, with research and development efforts centered on novel delivery devices and advanced imaging solutions.